Escalating doses of TRC 105 in combination with bevacizumab in patients with advanced bevacizumab- or VEGF TKI-refractory solid tumours

Trial Profile

Escalating doses of TRC 105 in combination with bevacizumab in patients with advanced bevacizumab- or VEGF TKI-refractory solid tumours

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Carotuximab (Primary) ; Bevacizumab
  • Indications Colorectal cancer; Ovarian cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 21 Nov 2013 New trial record
    • 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top